×

Targeted disruption of T cell receptor genes using talens

  • US 9,937,207 B2
  • Filed: 03/20/2014
  • Issued: 04/10/2018
  • Est. Priority Date: 03/21/2013
  • Status: Active Grant
First Claim
Patent Images

1. An isolated T-lymphocyte comprising a stably integrated exogenous sequence encoding a T-cell receptor (TCR), wherein at least one endogenous TCR gene within the cell is partially or completely inactivated by a nuclease, wherein the nuclease is a TALEN that binds to a target sequence site in the endogenous TCR gene, wherein said target sequence site is selected from SEQ ID NO:

  • 147-153, the TALEN comprising a TAL-effector DNA-binding domain and a cleavage domain, and further wherein the TAL-effector DNA-binding domain comprises a C-terminal truncation as compared to a wild-type TAL-effector DNA-domain.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×